LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer

Mengyu Feng¹, Guangbing Xiong¹,², Zhe Cao¹, Gang Yang¹, Suli Zheng¹, Jiangdong Qiu¹, Lei You¹, Lianfang Zheng³, Taiping Zhang¹,4* and Yupei Zhao¹*

Abstract

Background: Reprogrammed energy metabolism has become an emerging hallmark of cancer in recent years. Transporters have been reported to be amino acid sensors involved in controlling mTOR recruitment and activation, which is crucial for the growth of both normal and tumor cells. L-type amino acid transporter 2 (LAT2), encoded by the SLC7A8 gene, is a Na⁺-independent neutral amino acid transporter and is responsible for transporting neutral amino acids, including glutamine, which can activate mTOR. Previous studies have shown that LAT2 was overexpressed in gemcitabine-resistant pancreatic cancer cells. However, the role of LAT2 in chemoresistance in pancreatic cancer remains uncertain and elusive.

Methods: The effects of LAT2 on biological behaviors were analyzed. LAT2 and LDHB levels in tissues were detected, and the clinical value was evaluated.

Results: We demonstrated that LAT2 emerged as an oncogenic protein and could decrease the gemcitabine sensitivity of pancreatic cancer cells in vitro and in vivo. The results of a survival analysis indicated that high expression levels of both LAT2 and LDHB predicted a poor prognosis in patients with pancreatic cancer. Furthermore, we found that LAT2 could promote proliferation, inhibit apoptosis, activate glycolysis and alter glutamine metabolism to activate mTOR in vitro and in vivo. Next, we found that gemcitabine combined with an mTOR inhibitor (RAD001) could reverse the decrease in chemosensitivity caused by LAT2 overexpression in pancreatic cancer cells. Mechanistically, we demonstrated that LAT2 could regulate two glutamine-dependent positive feedback loops (the LAT2/p-mTORSer²⁴⁴⁸ loop and the glutamine/p-mTORSer²⁴⁴⁸/glutamine synthetase loop) to promote glycolysis and decrease gemcitabine (GEM) sensitivity in pancreatic cancer.

Conclusion: Taken together, our data reveal that LAT2 functions as an oncogenic protein and could regulate glutamine-dependent mTOR activation to promote glycolysis and decrease GEM sensitivity in pancreatic cancer. The LAT2-mTOR-LDHB pathway might be a promising therapeutic target in pancreatic cancer.

Keywords: L-type amino acid transporter 2, Mechanistic target of rapamycin, Pancreatic cancer, Chemoresistance, Glutamine metabolism, Glycolysis

* Correspondence: tpingzhang@yahoo.com; zhao8028@263.net
¹Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing Street, Beijing 100730, China
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Pancreatic cancer is one of the most lethal digestive tract malignancies, is difficult to detect early and has a poor prognosis. The 5-year overall survival rate has remained relatively stable, at close to 8%, over the past decade [1, 2]. Chemotherapy has become one of the primary and indispensable therapeutic methods. However, chemoresistance to gemcitabine (GEM), which is the first-line adjuvant therapy for pancreatic cancer, is prevalent and has become one of the key reasons that patients with pancreatic cancer show a poor prognosis. Therefore, elucidating the mechanism of chemoresistance to GEM may contribute to enhancing the effects of therapy and improving the prognosis of pancreatic cancer.

Reprogrammed energy metabolism has become an emerging hallmark of cancer in recent years [3]. Previous studies indicated that most metabolites did not show significant changes in pancreatic cancer cells exposed to GEM; however, chemoresistance to GEM induces metabolic reprogramming [4, 5]. Therefore, metabolic reprogramming must be involved in the regulation of chemoresistance. Glutamine and glucose are the primary nutrient sources for cancer cells and are crucial to the biosynthesis of products such as nucleic acids and non-essential amino acids (NEAAs) [6]. Otherwise, glutamine metabolism is involved in both glycolysis and the tricarboxylic acid (TCA) cycle. In addition, other studies show that glutamine can activate mechanistic target of rapamycin (mTOR) [7] and inhibit apoptosis to induce chemoresistance [8]. Thus, glutamine transport and metabolism might play an important role in chemoresistance in pancreatic cancer.

L-type amino acid transporter 2 (LAT2), encoded by the SLC7A8 gene, belongs to the SLC7 subfamily of the LAT family [9]. LAT2 is a Na⁺-independent neutral amino acid transporter and is responsible for transporting neutral amino acids, including Gln, Gly, Ser, Ala, Thr, Asn, Met, Val, Phe, Tyr, Leu, Ile, Trp and His [9, 10]. LAT2 is upregulated in 9 different cancer types according to Oncomine data [9]; however, few studies have proved its specific role in cancer, and the expression level and role of LAT2 in pancreatic cancer remain uncertain and elusive. In our previous study, we identified a cluster of dysregulated mRNAs associated with GEM chemoresistance via mRNA microarray analysis in the established gemcitabine-resistant pancreatic cancer cell line AsPC-1-GEM (data unpublished). Among these dysregulated mRNAs, LAT2 showed a higher expression level in AsPC-1-GEM cells (≥10-fold change) than in the parental cells. Thus, we presumed that LAT2 might be involved in the development and regulation of chemoresistance in pancreatic cancer. Given the previously described role of LAT2 in glutamine transport and metabolism, we hypothesized that LAT2 could promote GEM chemoresistance in pancreatic cancer cells through glutamine-dependent mTOR activation.

Methods
Patients, sample collection and immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded pancreatic cancer (n = 87) and matched paracancerous (n = 71) tissue microarrays were obtained from Peking Union Medical College Hospital. None of the patients received neoadjuvant therapy. Tumor staging relies on the 8th edition of TNM system designed by the American Joint Committee on Cancer (AJCC). Follow-up depended on medical records and telephone. The primary end point was overall survival. Mouse anti-human LAT2 monoclonal antibodies (GTX83618, GeneTex, 1:100) and rabbit anti-human LDHB polyclonal antibodies (14824–1-AP, Proteintech, 1:100) were used for the standard immunohistochemical staining procedures. The results of immunohistochemistry were scored by adding the percentage score and the intensity score, which were assessed according to the percentage of positive cells and intensity of staining respectively. The percentage score was classified into 4 grades using the percentage of positive cells (1, <25%; 2, 25–50%; 3, 50–75%; 4, >75%). The intensity score was classified into 4 grades using the intensity of stained cells (0, none; 1, weak; 2, moderate; 3, strong). LAT2 and LDHB expression was considered to be low if the total score was equal to or less than the median, and considered high if the score was greater than the median.

Cell culture
The human pancreatic cancer cell lines MIA PaCa-2 and PANC-1 were donated by Dr. Freiss H (University of Heidelberg, Heidelberg, Germany). MIA PaCa-2 and PANC-1 cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, Logan, UT, USA). All Media were supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan, UT, USA) at 37 °C and 5% CO₂.

Plasmids and antibodies
Complementary DNA encoding LAT2 was synthesized and subcloned into the pENTER-FLAG vector (Vigene Bioscience, MD, USA) according to the manufacturer’s instructions. For PANC-1 cell lines that stably overexpressed LAT2, the lentivirus plasmid plLVX-LAT2 was constructed by subcloning the LAT2 coding sequence (Gene ID: 23428) into the modified plLVX-puro backbone (Clontech, CA, USA). The forward primer was 5’-GCAGCTACTGCAATGGAAGAGGAGGCA-3’, and the reverse primer was 5’-CGGGGATCCGGGCTGGGCGCTGCC-3’. The PCR products of LAT2 coding sequence were inserted into the plLVX-puro plasmids with Nhe I and BamH I. The plLVX-LAT2 was packaged into lentiviruses. PANC-1 cells
were infected with the pLVX-LAT2 lentivirus, and the cell line was got after 2\(\mu\)g/ml puromycin screening.

Antibodies against LAT2 (GTX83618, GeneTex), LDHB (14824–1-AP, Proteintech), p-mTOR (Ser2448) (5536, Cell Signaling Technology), mTOR (2983, Cell Signaling Technology), PKM2 (4053, Cell Signaling Technology), GAPDH (10494–1-AP, Proteintech), Glutaminase (ab156876, Abcam) and Glutamine synthetase (sc-74430, Santa Cruz Biotechnology) were purchased commercially.

RNA interference
SiLAT2 and siNC were purchased from RiboBio (Guangzhou, China). The sequences for LAT2 siRNA are listed as below: the forward primer was 5'-GAAGAUGAU GAUGCCAAUUTT-3', and the reverse primer was 5'-AAUUGGCAUCAUCAUUCUTT-3'. MIA PaCa-2 and PANC-1 cells were transfected with siRNA at 50-100 nM packaged by Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) in 6-well plates (5 \(\times\) 10\(^5\) cells/well).

Lentivirus production
HEK293T cells were cultured in individual 15 cm dishes for each viral construction. When the cells reached approximately 70–80% confluency (~1.5 \(\times\) 10\(^5\) cells), they were cotransfected with 15 \(\mu\)g of the pLVX-LAT2 plasmid, 15 \(\mu\)g of the psPAX2 plasmid (Addgene #12260, Cambridge, MA, USA) and 10 \(\mu\)g of the pMD2.G plasmid (Addgene #12259, Cambridge, MA, USA) plasmid with Lipofectamine 2000 transfection reagent. At 18 h post-transfection, the medium was replaced with 25 mL of fresh complete medium. The supernatants were harvested at 48 h and 72 h, centrifuged at 1000 rpm for 10 min at 4 °C to remove the cells, and filtered through a 0.45 \(\mu\)m filter to remove the debris. Finally, the supernatant was ultracentrifuged at 120,000 \(\times\) g for 2 h at 4 °C, dissolved in PBS after the removal of the supernatant, and stored at ~80 °C.

CRISPR KO cell line construct
The target sequence was cloned into the lentivirus backbone (Addgene #52961, Cambridge, MA, USA) and two oligonucleotides were digested after digestion with BsmBI. The design of the target sequences was performed using http://crispr.mit.edu to obtain the gRNA sequence. The LAT2 gRNA forward primer sequence was 5'-CACCCTGACATCGGCCTCGTCGCAC-3', and the reverse primer sequence was 5'-AAACGTGCACAGGGCGGATGTGAC-3'. LentiCRISPR-LAT2sgRNA was packaged into the lentivirus. MIA PaCa-2 and PANC-1 cells were infected with the LentiCRISPR-LAT2sgRNA lentivirus for more than 48 h, and the cell lines were obtained 48 h after screening with 2 \(\mu\)g/ml puromycin. Then, the monoclonal cell lines were screened by identifying those with a knockout of LAT2 protein expression and a disturbance of the target DNA sequence.

Cell proliferation and growth inhibition assay
At 24 h after transfection, MIA PaCa-2 and PANC-1 cells were plated into 96-well culture plates (3000 cells/well) for cell proliferation assays. All the plates were cultured at 37 °C with 5% CO\(_2\). For proliferation assays, 10 \(\mu\)L/well cell count kit (CCK-8) reagent was added at 0, 24, 48 and 72 h after plated. After an additional 2.5-h incubation with CCK-8 reagent at 37 °C, the optical density (OD) at the 450-nm wavelength (OD\(_{450}\)) was measured using a microplate reader (Wellscan MK3, Thermo/Labsystems, Finland). OD630 served as a reference, and the OD in the blank well was used as the base level. For growth inhibition assays, 4000 cells/well were plated into 96-well culture plates at 24 h after transfection. After incubation for 4–6 h for cell adherence, a gemcitabine (Eli Lilly and Company) concentration gradient from 100 nM to 1 mM or control PBS buffer was added into each well. Cell count kit (CCK-8) reagent (10 \(\mu\)L/well) was added after an additional 48-h incubation at 37 °C. Then, the inhibition rate was calculated as follows: OD = OD\(_{450}\)-OD\(_{630}\), inhibition rate = 1-(OD\(_{GEM}\)-OD\(_{blank}\)) / (OD\(_{PBS}\)-OD\(_{blank}\)).

Apoptosis assay
MIA PaCa-2 and PANC-1 cells were transfected into 6-well plates and treated with 10 \(\mu\)M gemcitabine twenty-four hours later. After treating for 48 h, the cells were collected and resuspended in binding buffer. Next, the cells were stained with Annexin V-FITC and propidium iodide (PI) (Beyotime, China) according to the manufacturer’s instructions. Analyze was carried out using flow cytometry (FACScan, BD Biosciences, USA).

Metabolism experiments
The OCR and ECAR of cells were measured with an XF96 Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA, USA). Cells were plated (10,000 cells per well for MIA PaCa-2; 5000 cells per well for PANC-1) in at least triplicate for each condition the day before the experiment. The energy phenotype test and glycolytic rate assay were performed as described in the user guides for the Agilent Seahorse XF Cell Energy Phenotype Test Kit (103325–100, Agilent Technologies) and the Agilent Seahorse XF Glycolytic Rate Assay Kit (103344–100, Agilent Technologies). OCR and ECAR were normalized to the cell number as determined by CellTiter-Glo analysis at the end of the experiments.

Measurement of intracellular metabolites
The intracellular level of glutamine was determined by ultra-high-performance liquid chromatography-tandem
mass spectrometry (UHPLC-MS/MS) with glutamine as the target. A standard solution of L-glutamine was prepared, and calibration curves were drawn. The UHPLC separation was performed using an Agilent 1290 Infinity II series UHPLC system (Agilent Technologies) equipped with a Waters ACQUITY UPLC BEH amide column (100 × 2.1 mm, 1.7 μm). An Agilent 6460 triple quadrupole mass spectrometer (Agilent Technologies) equipped with an AJS electrospray ionization (AJS-ESI) interface was used for assay development. If the concentrations of the metabolites were beyond the linear range, the samples were diluted accordingly to put their concentrations within the range. The final concentration in nmol/L equals the calculated concentration multiplied by the dilution factor.

**Immunofluorescence assay**

PANC-1 cells were transfected in slide chambers (NUNC, Denmark) with Flag-LAT2 vector for 24 h. The cells were fixed in methanol, blocked with 10% FBS and then incubated with mouse anti-LAT2 or p-mTOR(Ser2448) antibody and rabbit anti-LDH2 antibody. The LAT2 and p-mTOR(Ser2448) staining were detected with an Alexa Fluor 488-labeled goat anti-mouse antibody and the LDHB staining was detected with an Alexa Fluor 647-labeled goat anti-rabbit antibody. DAPI was used for nuclear staining. Images were made using a Leica TCS SP2 microscope.

**Immunoblotting and immunoprecipitation**

After transfection for 48 h, total cellular protein was extracted with RIPA lysis buffer (Applygen, Beijing). Total protein (40 μg) was separated on a SDS-PAGE gel and then transferred to a PVDF membrane (Millipore, Billerica, MA). After blocking with 5% nonfat milk at room temperature for 1 h, the membrane was probed with primary antibodies (1:1000, Danvers, MA) overnight at 4 °C. The next day, the membrane was incubated with a horseradish peroxidase-conjugated secondary antibody (1:3000, Applygen, Beijing) at room temperature for 1 h. Proteins were detected by ECL reagents (Millipore, Billerica, MA). For immunoprecipitation, stable PANC-1 transfectants of the pENTER and pENTER LAT2 vectors were seeded in 6-well plates. The cells were then lysed in modified RIPA buffer. The cell lysates were incubated with antibody for 12 h at 4 °C on a rotating plate. The proteins were immunoprecipitated by protein A/G agarose beads (Santa Cruz, USA). The samples were resolved by SDS-PAGE and were subjected to immunoblot analysis.

**Animal experiments**

PANC-1 cells stably transfected with LAT2-lentiviral vectors or control lentiviral vectors were injected subcutaneously into the right flank of 6-week-old female BALB/c mice (Shanghai, Chinese Academy of Sciences, China) (5 × 10^6 cells in 250 μL of PBS per mouse). Each experimental group included five mice. Gemcitabine of 50 mg/kg or equal PBS were administered by intraperitoneal injection two weeks after tumor formation (tumor size between 100 and 200mm^3), followed by periodic booster shots every three days for two weeks. Tumor size was measured twice a week using a caliper to measure two perpendicular tumor diameters. Tumor volume was calculated based on the formula: volume (mm^3) = 1/2 × length × width^2. Tumor growth inhibition rate was calculated based on the formula: TGI % = (1-(Ti-T0) / (Ci-C0)) × 100. Ti = tumor volume after treatment with GEM, T0 = tumor volume prior to treatment with GEM, Ci = tumor volume after treatment with PBS, C0 = tumor volume prior to treatment with PBS. The tumor-bearing mice were euthanized on the 27th day.

**Statistical analysis**

Statistical analysis was performed using SPSS (version 19) and GraphPad PRISM 6 software. Statistical methods included the Wilcoxon signed rank test, Pearson chi-square test, two-tailed Student’s t-test, Kaplan-Meier survival analysis, and Cox proportional hazards regression analysis. All statistical tests included a two-way analysis of variance. Statistical significance was assumed when P < 0.05.

**Results**

A high LAT2 level is associated with a poor prognosis

The expression level of LAT2 in 87 pancreatic cancer tissue samples and 71 matched paracancerous tissues was evaluated by immunohistochemistry (IHC). The Wilcoxon signed rank test was applied to compare the difference in LAT2 expression between the 71 cancer and matched paracancerous tissues. The results revealed that the expression level of LAT2 in the pancreatic cancer tissues was higher than that in the paracancerous tissues (Fig. 1a, b, c, and d). The staining results were scored for high and low LAT2 expression, as depicted in the Materials and Methods section.

The correlation between the LAT2 expression level and the clinicopathological parameters was assessed, and no correlation was shown (see Additional file 1: Table S1). We also explored the correlation between the LAT2 level and the prognosis of pancreatic cancer. The mean follow-up time was 18.63 months (range 1–80 months). Survival analysis indicated that the overall survival rate of patients with a high LAT2 level was lower than that of patients with a low LAT2 level (P = 0.0154) (Fig. 1e). Univariate analysis indicated that lymph node staging (P = 0.049), differential degree (P = 0.002) and LAT2 expression level (P = 0.008) were the potential predictive factors for poor prognosis in pancreatic cancer (Table 1).
Multivariate analysis demonstrated that a high level of LAT2 was an independent risk factor for poor prognosis in pancreatic cancer ($P = 0.017$) (Table 1).

**LAT2 decreases gemcitabine sensitivity in vitro and in vivo**

To demonstrate the role of LAT2 in gemcitabine sensitivity in pancreatic cancer, we carried out growth inhibition assays to test the chemosensitivity of pancreatic cancer cells to gemcitabine in vitro and in vivo. As shown in Fig. 2a, b, c, and d, LAT2 knockdown (KD) increased the rate of GEM inhibition in MIA PaCa-2 and PANC-1 cells; in contrast, MIA PaCa-2 and PANC-1 cells with LAT2 overexpression (OE) were less sensitive to GEM than the control cells, which indicated that LAT2 might significantly enhance resistance to GEM in vitro and in vivo.

**Fig. 1** LAT2 is upregulated in pancreatic cancer. A The expression level of LAT2 in 71 pancreatic cancer tissue samples was higher than that in the matched paracancerous tissues ($P < 0.05$), B The Wilcoxon signed rank test was applied to compare the difference in LAT2 expression between the cancer and paracancerous tissues. C The expression of LAT2 in pancreatic cancer tissues was evaluated by immunohistochemistry. D The expression of LAT2 in pancreatic paracancerous tissues was evaluated by immunohistochemistry. 

**E** Kaplan-Meier survival analysis indicated that the overall survival time of the high-LAT2-level group is shorter than that of the low-LAT2-level group of patients with pancreatic cancer ($P = 0.0154$).
pancreatic cancer cells. Furthermore, we assessed the extracellular acidification rate (ECAR) in LAT2 KD/OE pancreatic cancer cells exposed to GEM and obtained a similar result, which demonstrated that LAT2 could increase ECAR to enhance chemoresistance and that GEM might inhibit the proliferation of pancreatic cancer cells by decreasing ECAR (Fig. 2e, f, g and h). To further determine the effects of LAT2 on chemosensitivity in vivo, we established PANC-1 cell lines that stably overexpressed LAT2 (pLVX-PANC-1-LAT2), subcutaneously injected these cells into nude mice, and then treated the mice with chemotherapy (GEM). The in vivo results revealed that, in mice treated with gemcitabine, the tumors generated from the pLVX-PANC-1-LAT2 cells grew significantly faster than those generated from the control cells \((P<0.05)\) (Fig. 2i). In addition, both the tumor volume and weight in the pLVX-PANC-1-LAT2 group were significantly larger than those in the control group \((P<0.05)\) (Fig. 2i, j, and k). Then, the tumor growth inhibition (TGI) rate was calculated, and the results showed that the TGI% in the pLVX-PANC-1-LAT2 group was significantly lower than that in the control group (Fig. 2k). Taken together, these results suggest that LAT2 decreases the gemcitabine sensitivity of pancreatic cancer cells in vitro and in vivo.

### LAT2 promotes pancreatic cancer cell proliferation in vitro and in vivo

We also assessed the role of LAT2 in proliferation by LAT2 KD/OE in pancreatic cancer cells. As shown in Additional file 2: Figure S1 A-D, LAT2 overexpression significantly promoted proliferation, whereas LAT2 knockdown significantly suppressed proliferation, in MIA PaCa-2 and PANC-1 cells compared with the

| Table 1 | Univariate and multivariable analyses of factors predictive of poor overall survival in pancreatic cancer patients |
|---------|---------------------------------------------------------------|
| Variables | Univariate analysis | Multivariate analysis |
|          | Overall survival (Median ± SE, months) | 95% confidence interval | P value | Hazard ratio | 95% confidence interval | P value |
| Sex      | 10 ± 1.063 | 7.917–12.083 | 0.726 | 7.917–12.083 | 2.311–19.689 |
| Male     | 11 ± 4.433 | 2.311–19.689 |
| Female   | 11 ± 0.980 | 9.078–12.922 | 0.379 | 11 ± 4.433 | 2.311–19.689 |
| Age (years old) | 7 ± 0.833 | 5.367–8.633 | 0.234 | 7 ± 0.833 | 5.367–8.633 |
| <65      | 10 ± 1.440 | 7.178–12.822 | 0.280 | 10 ± 1.440 | 7.178–12.822 |
| ≥ 65     | 10 ± 1.571 | 6.921–13.079 |
| Locations | 10 ± 1.571 | 6.921–13.079 |
| Head     | 10 ± 1.571 | 6.921–13.079 |
| Body-tail | 10 ± 1.571 | 6.921–13.079 |
| Perineuronal/vascular/lymphatic invasion | 10 ± 1.571 | 6.921–13.079 |
| No       | 11 ± 2.60 | 5.905–16.095 |
| Yes      | 10.0 ± 0.957 | 8.125–11.875 |
| Tumor staging | 10.0 ± 1.701 | 7.646–12.354 | 0.594 | 10.0 ± 1.701 | 7.646–12.354 |
| T1/T2    | 10.0 ± 1.474 | 7.112–12.888 |
| T3/T4    | 10.0 ± 1.474 | 7.112–12.888 |
| Lymph node staging | 0.049 | 2.053 | 1.228–3.433 | 0.006 | 2.053 | 1.228–3.433 |
| N0       | 10 ± 1.201 | 7.646–12.354 |
| N1/N2    | 10 ± 1.474 | 7.112–12.888 |
| Differential degree | 0.002 | 2.737 | 1.614–4.644 | 0.000 | 2.737 | 1.614–4.644 |
| High/ moderate | 0.002 | 2.737 | 1.614–4.644 |
| Low      | 10 ± 3.499 | 3.141–16.859 |
| TNM staging | 10 ± 3.499 | 3.141–16.859 |
| I        | 10 ± 1.474 | 7.112–12.888 |
| II/III   | 10 ± 1.474 | 7.112–12.888 |
| LAT2 expression | 10 ± 1.474 | 7.112–12.888 |
| Low      | 10 ± 1.474 | 7.112–12.888 |
| High     | 10 ± 1.474 | 7.112–12.888 |

Feng et al. Journal of Experimental & Clinical Cancer Research (2018) 37:274
Fig. 2 (See legend on next page.)
In addition, we established the pLVX-PANC-1-LAT2 cell line and subcutaneously injected cells from this line into nude mice. Based on the growth inhibition results of PBS control group, both the tumor volume and weight in the pLVX-PANC-1-LAT2 group were significantly larger than those in the control group ($P < 0.05$) (Fig. 2i, j, and k). As shown in Fig. 2i, the tumors grew significantly faster in the pLVX-PANC-1-LAT2 group than in the control group ($P < 0.05$). In summary, these data indicate that LAT2 promotes pancreatic cancer cell proliferation in vitro and in vivo.

**LAT2 inhibits pancreatic cancer cell apoptosis**

To identify the effects of LAT2 on apoptosis in pancreatic cancer cells, we detected the apoptosis rate and apoptosis-related protein changes induced by LAT2 KD/OE in MIA PaCa-2 and PANC-1 cells. As shown in Additional file 2: Figure S2 A-D, siLAT2 significantly increased the percentage of apoptotic MIA PaCa-2 and PANC-1 cells, whereas LAT2 overexpression significantly decreased this percentage compared with the siNC cells. Simultaneously, the results of Western blot analysis revealed that Bax and cleaved caspase-7 were upregulated in MIA PaCa-2 and PANC-1 cells transfected with siLAT2, whereas p21 was downregulated in these cells (Additional file 2: Figure S2 E). In addition, the opposite results were observed in MIA PaCa-2 and PANC-1 cells with LAT2 OE (Additional file 2: Figure S2 E).

**LAT2 activates pancreatic cancer cells glycolysis and alters glutamine metabolism to promote mTOR activation in vitro and in vivo**

We also confirmed the role of LAT2 in glycolysis and glutamine metabolism in pancreatic cancer cells. ECAR, cell energy phenotype and proton efflux rate from glycolysis (glycoPER) were measured with an XF96 Extracellular Flux Analyzer. As shown in Fig. 3a and b, ECAR was increased in MIA PaCa-2 and PANC-1 cells with LAT2 OE and was decreased in cells transfected with siLAT2. We then measured the metabolic phenotype changes, and the results indicated that LAT2 could promote the transformation from a quiescent to a glycolytic or an energetic metabolic phenotype. We also confirmed that LAT2 increased glycoPER in MIA PaCa-2 and PANC-1 cells with LAT2 OE compared with the control cells, and vice versa (Fig. 3d). In addition, we detected the protein levels of mTOR pathway and key enzymes involved in the regulation of glycolysis and glutamine metabolism. The results revealed that LAT2 OE increased the levels of LDHB and PKM2, both of which are key molecules involved in promoting glycolysis. In contrast, LAT2 OE could decrease the level of glutaminase and increase the level of glutamine synthetase (Fig. 3e).

**LAT2 binds to p-mTORSer2448 to upregulate LDHB and activate glycolysis**

To further explore the mechanisms by which LAT2 regulates lactate dehydrogenase B (LDHB) and glycolysis, we performed immunofluorescence and coimmunoprecipitation assays to confirm the relationship between LAT2 and LDHB. As shown in Figs. 3e and 4a, b, c, d and e, LAT2 increased mTOR phosphorylation and upregulated LDHB in MIA PaCa-2 and PANC-1 cells;
however, the mTOR inhibitor RAD001 could downregulate LDHB. LAT2 was localized in the cytomembrane and cytoplasm; however, p-mTOR and LDHB were all localized in the cytoplasm. Then, coimmunoprecipitation was used to confirm that LAT2 could bind to p-mTOR\(^{\text{Ser2448}}\) to activate mTOR and that p-mTOR\(^{\text{Ser2448}}\) could bind to LDHB to upregulate its expression level (Fig. 4b and c). Glycolysis could be enhanced by LDHB upregulation. Taken together, these data indicate that LAT2 binds to p-mTOR\(^{\text{Ser2448}}\) to upregulate LDHB and activate glycolysis.

**RAD001 reverses the LAT2-induced decrease in chemosensitivity**

We also assessed the role of mTOR in the GEM sensitivity of pancreatic cancer cells. LAT2 suppressed apoptosis in pancreatic cancer cells with LAT2 OE; this suppression could be reversed by RAD001 treatment. Otherwise, GEM could induce apoptosis in pancreatic cancer cells, and RAD001 could reverse the inhibition of apoptosis induced by GEM in pancreatic cancer cells with LAT2 OE (Fig. 5a and b). Simultaneously, RAD001 could increase the GEM sensitivity of LAT2 OE pancreatic cancer cells (Fig. 5c). The above results demonstrate that RAD001 reverses the LAT2-induced decrease in chemosensitivity in pancreatic cancer cells.

**RAD001 reverses the LAT2-induced activation of glycolysis**

To identify the effects of mTOR on glycolysis in pancreatic cancer cells, we then detected ECAR and glycoPER in MIA PaCa-2 and PANC-1 cells with LAT2 OE that
were treated with RAD001. As shown in Fig. 5d, e, f and g, the results revealed that both ECAR and glycoPER were increased in the LAT2 OE pancreatic cancer cells compared with the control cells and that this increase could be reversed by RAD001 treatment. In contrast, RAD001 treatment could downregulate the expression levels of LDHB and glutamine synthetase in MIA PaCa-2 and PANC-1 cells with LAT2 OE (Fig. 5h). LDHB is involved in glycolysis regulation, and glutamine synthetase is involved in glutamine metabolism. Thus, the above data indicate that RAD001 reverses LAT2-induced activation of glycolysis.

A high LDHB level is associated with a poor prognosis

Then, we detected the expression level of LDHB in 87 pancreatic cancer tissue samples and 71 matched paracancerous tissues using IHC, with two cases of IHC failure. The results indicated that the expression level of LDHB in the cancer tissues was higher than that in the paracancerous tissues (Additional file 2: Figure S4 A-C).

We also investigated the correlation between the LDHB expression level and the prognosis of pancreatic cancer. The survival analysis results revealed that the overall survival time of patients with a high LDHB level was shorter than that of those with a low LDHB level ($P = 0.0292$) (Additional file 2: Figure S4 D). Further analysis indicated that the overall survival time of patients with high levels of LDHB and LAT2 expression was shorter than that of those with other LDHB and LAT2 statuses ($P = 0.0044$) (Additional file 2: Figure S4 E). Thus, these results indicate that high levels of both LDHB and LAT2 are associated with a poor prognosis.
LAT2 targets glutamine-dependent mTOR activation to regulate apoptosis, glycolysis and chemosensitivity in pancreatic cancer cells

Then, we investigated whether the process by which LAT2 targets mTOR activation to regulate apoptosis, glycolysis and chemosensitivity in pancreatic cancer cells was dependent on glutamine. As shown in Fig. 6a, b, d, and e, the percentage of apoptotic cells in both MIA PaCa-2 and PANC-1 cells with LAT2 OE were higher than that in the control cells when the L-glutamine concentration was normal (4 mM); however, glutamine deprivation (L-glutamine concentration 0 mM) could reverse the LAT-2 induced decrease in the percentage of apoptotic cells. Similarly, glutamine deprivation could reverse the LAT2-induced increase in ECAR and glycoPER in MIA PaCa-2 and PANC-1 cells with LAT2 overexpression compared with the control cells, and this increase could be reversed by RAD001. h RAD001 downregulated the expression of LDHB and glutamine synthetase in MIA PaCa-2 and PANC-1 cells with LAT2 overexpression; RAD001 downregulated LAT2 expression in PANC-1 cells with LAT2 overexpression. i LAT2 knockout upregulated glutaminase expression, inhibited the mTOR pathway (thereby downregulating p-4EBP1) and downregulated AMPKα1/2 expression; and gemcitabine suppressed the mTOR pathway in PANC-1 cells dependent on LAT2. The data are presented as the mean ± SD. (Student’s t-test; *, P < 0.05)
Interestingly, the previous results indicated that LAT2 could bind to p-mTOR Ser2448 to upregulate LDHB and activate glycolysis; however, glutamine deprivation promoted the dissociation of LAT2 and p-mTORSer2448 (Fig. 6h). Taken together, the above results demonstrate that LAT2 targets glutamine-dependent mTOR activation to regulate apoptosis, glycolysis and chemosensitivity in pancreatic cancer cells.

**LAT2 interacts with p-mTORSer2448 to activate glycolysis, increase intracellular glutamine levels and decrease GEM sensitivity in pancreatic cancer cells**

Next, we explored the mechanisms by which LAT2 regulates glutamine metabolism. As shown in Fig. 7a, b, and c, the results indicated that RAD001 could downregulate glutamine synthetase in MIA PaCa-2 and PANC-1 cells and that the levels of both p-mTORSer2448 and glutamine synthetase are decreased in pancreatic cancer cells with CRISPR/Cas9-mediated knockout of LAT2 (LAT2 KO). Without LAT2 KO, p-mTOR bound to glutamine synthetase to upregulate the expression level of glutamine synthetase. Thus, the above data and previous data indicated that LAT2 could bind to p-mTORSer2448 to upregulate glutamine synthetase expression, which could increase the intracellular level of glutamine in pancreatic cancer cells. Next, we further assessed the interaction between LAT2 and p-mTORSer2448. As shown in Fig. 5h, the results revealed that RAD001 treatment could conversely downregulate LAT2 expression in PANC-1 cells with LAT2 OE.
KO could also upregulate glutaminase expression, inhibit the mTOR pathway (thereby downregulating p-4EBP1) and downregulate AMPKα1/2 expression. In contrast, GEM could inhibit the mTOR pathway in PANC-1 cells dependent on LAT2 (Fig. 5i). Combined with the previous results, these results demonstrated that LAT2 could increase the intracellular level of glutamine and bind to p-mTORSer2448 to upregulate the levels of LDHB and glutamine synthetase. Then, the upregulated LDHB could activate glycolysis and decrease GEM sensitivity in pancreatic cancer, and the increased glutamine synthetase and decreased glutaminase could further increase the level of intracellular glutamine, which is indispensable for mTOR activation. However, RAD001 treatment could also inhibit LAT2. Consequently, LAT2 interacts with p-mTORSer2448 to activate glycolysis, increase the intracellular level of glutamine and decrease the GEM sensitivity of pancreatic cancer cells.

Discussion

In humans, the specific role of LAT2 in pancreatic cancer has not been reported and is still elusive. Our previous study has demonstrated that the expression level of LAT2 in AsPC-1-GEM cells is higher than that in the parental cells, which might indicate that LAT2 plays an important role in chemoresistance in pancreatic cancer. Chemoresistance is regarded as one of the primary causes of poor prognosis and high mortality in pancreatic cancer. In this study, we identified LAT2 as a novel oncogenic protein in pancreatic cancer. We found that the expression levels of both LAT2 and LDHB in pancreatic cancer tissues were higher than those in the paracancerous tissues and that high levels of both LAT2 and LDHB were associated with poor prognosis. In addition, LAT2 could decrease GEM sensitivity, promote proliferation, inhibit apoptosis and activate glycolysis in pancreatic cancer cells, and these effects could be reversed by RAD001 treatment. Mechanistically, LAT2 could regulate the glutamine/p-mTORSer2448/glutamine synthetase feedback loop to keep mTOR activated and to upregulate LDHB in order to activate glycolysis, thereby promoting chemoresistance in pancreatic cancer cells. We also demonstrated that the decreased apoptosis and increased ECAR and glycoPER induced by the LAT2-mTOR-LDHB pathway in pancreatic cancer cells were dependent on glutamine. Consequently, our data indicate that the LAT2-mTOR-LDHB pathway might be a valuable prognostic predictor and promising therapeutic target in pancreatic cancer.

LAT2 has been reported to play different roles in multiple tumor types. Barollo et al. confirmed that LAT2 was overexpressed in neuroendocrine tumors, including pheochromocytoma and medullary thyroid carcinoma, compared with normal tissues and that it was responsible for dihydroxyphenylalanine uptake [11]. Luo et al. found that LAT2 might play important roles in the proliferation of uterine leiomyoma cells [12]. In breast cancer, SLC7A8 mRNA expression was elevated in samples from estrogen receptor alpha-positive breast cancer patients. However, a high level of SLC7A8 mRNA was significantly associated with longer relapse-free survival in estrogen receptor alpha-positive and lymph node-positive breast cancer patients [13]. Our study demonstrated that a high LAT2 level was associated with poor overall survival in pancreatic cancer. In terms of chemosensitivity, Rumiato et al. found that single nucleotide polymorphisms mapping to the SLC7A8 gene, in combination with clinical variables, could contribute to the accuracy of the predicted response to platinum chemotherapy in esophageal cancer patients [14]. Meanwhile, another
study showed that the expression of the SLC7A8 gene was significantly decreased in the paclitaxel-resistant W1 human ovarian cancer cell line compared with W1 parental cells; thus, SLC7A8 might be involved in reversing drug resistance in ovarian cancer [15]. However, in our previous study, LAT2 showed a higher expression level in AsPC-1-GEM cells than in the parental cells. In this study, we also demonstrated that LAT2 played an oncogenic role in pancreatic cancer and could decrease GEM sensitivity by regulating the glutamine-dependent LAT2-mTOR-LDHB pathway.

Glutamine addiction is a feature of many cancer types. Glutamine, a major source of carbon and nitrogen for sustaining the proliferation of cancer cells, has been reported to be critical for proliferation in pancreatic cancer [16–18]. Otherwise, oncogenic alterations in genes such as MYC and KRAS could reprogram glutamine metabolism in cancer cells [8]. For example, c-MYC has been demonstrated to bind to the promoter regions of high-affinity glutamine importers, thereby causing increased glutamine uptake, and oncogenic KRAS could upregulate enzymes involved in glutamine metabolism [19, 20]. Jewell et al. have demonstrated that glutamine could activate mTORC1, which is important for the growth of both normal and tumor cells [7]. Recent studies have indicated that transporters act as amino acid sensors involved in controlling mTOR recruitment and activation at the surface of multiple intracellular compartments. We have demonstrated that LAT2 could bind to p-mTOR to regulate the glutamine/p-mTORSer2448/glutamine synthetase feedback loop, resulting in an increased intracellular level of glutamine and the sustained activation of mTOR. In contrast, LAT2 could downregulate glutaminase to further increase the intracellular level of glutamine. Activated mTOR could bind to and upregulate LDHB to increase glycolysis and decrease chemosensitivity. Glutamine deprivation could then cause mTOR activation failure and decreased glycolysis. We also demonstrated that RAD001 treatment could downregulate LAT2, which indicated that mTOR activation might contribute to maintaining LAT2 stability. Therefore, LAT2 could bind to p-mTORSer2448, and they could interact with each other to form a positive feedback loop. Next, p-mTORSer2448 could bind to and upregulate glutamine synthetase to increase endogenous glutamine levels, thereby forming another positive feedback loop (glutamine/p-mTORSer2448/glutamine synthetase). Meanwhile, mTOR activation depends on exogenous glutamine. Therefore, both positive feedback loops are dependent on exogenous glutamine.

RAD001, a mTOR inhibitor, has been approved for the treatment of pancreatic cancer; however, treatment with single mTOR inhibitors can lead only to disease stabilization rather than regression because mTOR contributes to cellular proliferation rather than cell survival [21]. In this study, we have demonstrated that RAD001 treatment could reverse the decrease in GEM sensitivity caused by LAT2 overexpression in pancreatic cancer. These results indicate that GEM combined with RAD001 might improve chemosensitivity in pancreatic cancer patients with LAT2 overexpression.

In terms of the relationship between mTOR and LDHB, Zha et al. demonstrated that LDHB, which is critical for oncogenic mTOR-mediated tumorigenesis, is a downstream target of mTOR [22]. Our study also confirmed that LAT2 could target mTOR activation to regulate LDHB, which is critical for the conversion of pyruvate to lactate. Then, we assessed the role of the LAT2-mTOR-LDHB pathway in glycolysis, and the results indicated that both LAT2 KD and mTOR inhibition could downregulate LDHB, decrease glycoPER and inhibit glycolysis. In contrast, increased glycoPER has been reported to be associated with decreased chemosensitivity. In addition, we have demonstrated that RAD001 treatment could reverse the decrease in GEM sensitivity induced by LAT2 OE. Therefore, we speculated that LAT2 could regulate the above two positive feedback loops to upregulate LDHB and activate glycolysis, which would promote chemoresistance in pancreatic cancer. However, Cui et al. found that LDHB might act as a suppressor of glycolysis and as a tumor suppressor gene in pancreatic cancer due to promoter hypermethylation [23]. Conversely, a recent study indicated that positive LDHB protein expression was associated with progression and poor prognosis in patients with pancreatic cancer [24]. Otherwise, LDHB has been reported to be an oncogenic protein in multiple tumor types, including uterine cancer, ovarian cancer, colon cancer and breast cancer [25–27]. In this study, we demonstrated that a high LDHB level is associated with poor prognosis in pancreatic cancer.

Conclusion
In conclusion, we have demonstrated that LAT2 could regulate two glutamine-dependent positive feedback loops (the LAT2/p-mTORSer2448 loop and the glutamine/p-mTORSer2448/glutamine synthetase loop) to promote glycolysis and decrease GEM sensitivity in pancreatic cancer. In addition, high levels of both LAT2 and LDHB are poor prognostic predictors in pancreatic cancer. Finally, GEM combined with RAD001 could increase GEM sensitivity in pancreatic cancer patients with LAT2 OE. Therefore, the LAT2-mTOR-LDHB pathway might be a promising therapeutic target in pancreatic cancer, and further study should be conducted to investigate the specific mechanisms between the two positive feedback loops.
Additional files

**Additional file 1: Table S1.** Correlations of LAT2 level in tissues and clinicopathological parameters. (DOC 44 kb)

**Additional file 2: Figure S1.** LAT2 promotes pancreatic cancer cell proliferation. (A, C) Overexpression of LAT2 in MIA PaCa-2 and PANC-1 cells promoted cell proliferation. (B, D) LAT2 knockdown suppressed cell proliferation. (*, \(P < 0.05\)). Figure S2. LAT2 inhibits pancreatic cancer cell apoptosis. (A, C) LAT2 knockdown in MIA PaCa-2 and PANC-1 cells increased the percentage of apoptotic cells compared with the control. (B, D) Overexpression of LAT2 decreased the percentage of apoptotic cells compared with the control. (E) The Western blotting results revealed that Bax and cleaved caspase-7 were upregulated in MIA PaCa-2 and PANC-1 cells transfected with siLAT2, whereas p21 was downregulated; contrary results were achieved when the cells were transfected with LAT2 OE plasmids. (*, \(P < 0.05\)). Figure S3. LAT2 activates glycolysis and alters glutamine metabolism in vivo. The IHC results revealed that the levels of LAT2, LDHB, p-mTOR\(^{1298}\) and glutamine synthetase were increased in tumors generated from pLVX-PANC-1-LAT2 mice in nude mice compared with those in tumors generated from the control cells, whereas the level of glutaminase was decreased. Figure S4. A high LDHB level is associated with poor prognosis in pancreatic cancer. (A) The Wilcoxon signed rank test was applied to compare the difference in LDHB expression between cancer and paracancerous tissues. (B, C) The expression level of LDHB in 69 pancreatic cancer tissue samples was higher than that in the matched paracancerous tissues (*, \(P < 0.05\)). (D, E) Kaplan-Meier survival analysis indicated that the overall survival rate of the high-LDHB and high-LAT2 level group is poorer than that of pancreatic cancer patients with other LDHB and LAT2 statuses (\(P = 0.0044\)). Figure S5. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and decrease gemcitabine sensitivity. This diagram shows the mechanisms by which LAT2 regulates glycolysis and gemcitabine sensitivity in pancreatic cancer. ASCT2, ASC family transporter 2 (also called SLC1A5). (ZIP 7755 kb)

Abbreviations

AJCC: American Joint Committee on Cancer; ECAR: Extracellular acidification rate; GEM: Gemcitabine; glycoPER: Proton efflux rate from glycolysis; IHC: Immunohistochemistry; KD: Knockdown; LAT2 KO: Knockout of LAT2; LAT2: L-type amino acid transporter 2; LDHB: Lactate dehydrogenase B; mTOR: Mechanistic target of rapamycin; NEAAs: Nonessential amino acids; OD: Optical density; OE: Overexpression; TCA: Tricarboxylic acid cycle; UHPLC-MS/MS: Ultra-high-performance liquid chromatography- tandem mass spectrometry.

Acknowledgements

The authors acknowledge the contribution of all the investigators at the participating study sites. We thank Dr. Yan Zhao for the CRISPR/Cas9 technology.

Funding

This study was supported by grants from the National Natural Science Foundation of China (No. 81772639, No. 81472327), the Major State Basic Research Development Programme of China (973 Programme; No. 2014CB542300), the Chinese Academy Medical Science Innovation Fund for Medical Sciences (No. 2016L2M-1-001), and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (No. 2018PT32014; No. 2018PT32002).

Availability of data and materials

The data supporting the conclusions of this article are included within the article.

Authors’ contributions

MF carried out the molecular genetic and metabolism studies, participated in the sequence alignment and drafted the manuscript. MF, GX and ZC carried out the animal experiments and sample collection. GY, SZ and JQ carried out IHC. LY and LZ participated in statistical analysis. TZ and YZ conceived of the study and participated in its design and coordination. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study has been conducted in accordance with ethical standards and according to the Declaration of Helsinki and the national and international guidelines, and has been approved by the authors’ institutional review board. All processes involving animals and patients were approved by the Institutional Review Boards of Peking Union Medical College Hospital (PUMCH). Animal experiments were performed according to the guidelines of the Experimental Animals Management Committee. Written informed consent was obtained from all subjects.

Consent for publication

Informed consent for publication was obtained and is available for review by the editor.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuafuyuan, Wangfujing Street, Beijing 100730, China. 2Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. 3Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. 4Clinical Immunology Center, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuafuyuan, Wangfujing Street, Beijing 100730, China.

Received: 19 July 2018 Accepted: 29 October 2018

Published online: 12 November 2018

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
2. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37.513.025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
4. Todaka A, Umehara R, Sasaki K, Serizawa M, Utakami K, Kusuhara M, et al. Metabolic profiling of gemcitabine- and paclitaxel-treated immortalized human pancreatic cell lines with K-RAS(G12D). Biores. Res. 2017;38(1):29–40.
5. Grasso C, Jansen G, Giovannetti E. Drug resistance in pancreatic cancer: impact of altered energy metabolism. Crit Rev Oncol Hematol. 2017;114:139–52.
6. Coloff JL, Murphy JP, Braun CR, Harris IS, Shelton LM, Kami K, et al. Differential glutamate metabolism in proliferating and quiescent mammary epithelial cells. Cell Metab. 2016;23(5):867–80.
7. Jewell JL, Kim YC, Russell RC, Yu FX, Park HW, Piouffe SW, et al. Metabolism. Differential regulation of mTORC1 by leucine and glutamine. Science. 2015;347(6218):194–8.
8. Yang L, Venneti S, Nagrath D. Glutaminolysis: a Hallmark of Cancer metabolism. Annu Rev Biomed Eng. 2017;19:163–94.
9. Wang Q, Holst J. L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia. Am J Cancer Res. 2015;5(4):1281–94.
10. Segawa H, Fukasawa Y, Miyamoto K, Takeda E, Endou H, Kanai Y. Identification and functional characterization of a Na+–independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem. 1999;274(28):19745–51.
11. Barollo S, Bertazza L, Wat utantri-ge-Fernando S, Ceni S, Cavedon E, Galuppi F, et al. Overexpression of L-type amino acid transporter 1 (LAT1) and 2 (LAT2) novel markers of neuroendocrine tumors. PLoS One. 2016;11(5):e0156044.
chain expression in uterine leiomyoma cells. J Clin Endocrinol Metab. 2009; 94(11):4533–9.

13. Thakkar A, Raj H, Ravishankar MB, Balakrishnan A, Padigaru M. High expression of three-gene signature improves prediction of relapse-free survival in estrogen receptor-positive and node-positive breast tumors. Biomark Insights. 2015;10:103–12.

14. Rumiato E, Boldrin M, Maladetta S, Battaglia G, Bocci P, Castoro C, et al. A germline predictive signature of response to platinum chemotherapy in esophageal cancer. Transl Res. 2016;171:29–37 e21.

15. Januchowski R, Zawierucha P, Andrzejewska M, Rucinski M, Zabel M. Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. Biomed Pharmacother. 2013;67(3):240–5.

16. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496(7443):101–5.

17. Halbrook CJ, Lyssiotis CA. Employing metabolism to improve the diagnosis and treatment of pancreatic Cancer. Cancer Cell. 2017;31(1):5–19.

18. Lyssiotis CA, Son J, Cantley LC, Kimmelman AC. Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance. Cell Cycle. 2013;12(13):1987–8.

19. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105(48):18782–7.

20. Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol. 2011;7:523.

21. Kim LC, Cook RS, Chen J. mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene. 2017;36(16):2191–201.

22. Zha X, Wang F, Wang Y, He S, Jing Y, Wu X, et al. Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorogenesis. Cancer Res. 2011; 71(1):3–8.

23. Cui J, Quan M, Jiang W, Hu H, Jiao F, Li N, et al. Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype. Med Oncol. 2015;32(5):143.

24. Luo Y, Yang Z, Li D, Liu Y, Yang L, Zou Q, et al. LDHB and FABP4 are associated with progression and poor prognosis of pancreatic ductal adenocarcinomas. Appl Immunohistochem Mol Morphol. 2017;25(5):351–7.

25. Brisson L, Banski P, Sboarina M, Dethier C, Danhier P, Fontenille MJ, et al. Lactate dehydrogenase B controls lysosome activity and autophagy in Cancer. Cancer Cell. 2016;30(3):418–31.

26. Fu D, Li J, Wei J, Zhang Z, Luo Y, Tan H, et al. HMGB2 is associated with malignancy and regulates Warburg effect by targeting LDHB and FB1 in breast cancer. Cell Commun Signal. 2018;16(1):8.

27. Smith B, Schafer XL, Ambeskovic A, Spencer CM, Land H, Munger J. Addiction to coupling of the Warburg effect with glutamine catabolism in Cancer cells. Cell Rep. 2016;17(3):821–36.